### Learner Notification

**Society of Gynecologic Oncology**

**2022 Welcoming Spaces – Module #7 - Considerations During and After Gynecologic Cancer Care for Transgender Patients**

**Enduring: June 22, 2022 – June 22, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

GSK Astra Zeneca

Seagen Merck

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians (ACCME) Credit Designation**

Amedco LLC designates this **live activity** for a maximum of **1.0** *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of **1.0 Live** ANCC contact hours.

**Pharmacists and Pharmacy Technicians (ACPE) Credit Designation**

Amedco LLC designates this activity for a maximum of **1.0 Live** knowledge-based CPE contact hours.

**NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

###### Objectives - After Attending This Program You Should Be Able To

1. Review specific cases of trans men with gynecologic cancers.
2. Identify the link between onco-fertility and transgender fertility and review available fertility options for trans people.
3. Recognize the specific comorbidities, mental health concerns, and other considerations facing trans and nonbinary cancer survivors.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Do you have any financial relationships with ineligible companies to disclose?** |
| Ethel Dawn | Capone | Nothing to Disclose |
| Don | Dizon | Clovis, Regeneron, Pfizer, Oasmia & Asta Zzeneca - Consultant |
| Monique | Gary | Nothing to Disclose |
| Cecilia | Hardacker | Nothing to Disclose |
| Bill | Jesdale | Nothing to Disclose |
| Teri | Jordan | Nothing to Disclose |
| Aurea | Kasberg | Bristol Myers Squibb, Servier, GlaxoSmithKline, & Genentech - Grant Recipient |
| Aurea | Kasberg | Nothing to Disclose |
| Lisa | Kaszubski | Nothing to Disclose |
| Nina | Kennedy | Nothing to Disclose |
| Allison | Knuth | Nothing to Disclose |
| Knoll | Larkin | Nothing to Disclose |
| Pam | Lewis | Nothing to Disclose |
| Phoenix | Matthews | Nothing to Disclose |
| Jennifer | Meade | Nothing to Disclose |
| Lauren | Nocera | Nothing to Disclose |
| Gwendolyn | Quinn | CME Outfitter - Speakers' Bureau, Honoraria/Reimbursement |
| Gwendolyn Quinn | Quinn | Nothing to Disclose |
| Gwendolyn | Quinn | Nothing to Disclose |
| BJ | Rimel | GSK, AstraZeneca, & Merck - Advisory Board Participant; Deep6AI, & Tempus - Consultant |
| Polly | Rossi | Nothing to Disclose |
| Tracy | Sandstrom | Nothing to Disclose |
| NFN | Scout | Syros Pharmaceuticals, Servier Pharmaceuticals, Bristol Myers Squibb, Glaxo Smith Klein, & Genentech - Grant Recipient |
| Zul Surani | Surani | Nothing to Disclose |
| Karl | Surkan | Nothing to Disclose |
| Christopher | Wheldon | Nothing to Disclose |
| Erin | Zink | Nothing to Disclose |